In our study, the median age at the onset of breast cancer was slightly younger for HR − /HER2 + tumors than for HR + /HER2 −  tumors (31 years and 35.5 years, respectively), although our study was limited by a small sample size. Here, ERBB2 is linked to breast cancer.